Scientists Discover a Hidden Cancer-Fighting Switch That Could Supercharge the Immune System

Image Courtesy: Shutterstock

Scientists have identified a potential way to make engineered human immune cells more effective at fighting cancer by temporarily activating p53, a protein best known for preventing damaged cells from becoming cancerous.

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that activating p53 during the preparation of engineered T cells helped the cells develop characteristics associated with longer-lasting immune responses. In laboratory experiments, the modified cells were also significantly more effective at killing melanoma cells.

The findings could be relevant to CAR T-cell and T-cell receptor therapies, which involve collecting a patient’s immune cells, genetically modifying them to recognize cancer, and returning them to the body. These treatments have transformed care for some blood cancers but remain difficult to adapt effectively to solid tumors.

One major challenge is T-cell exhaustion. Repeated exposure to cancer can cause immune cells to lose their ability to multiply and attack tumors. The laboratory process used to prepare engineered cells can also push them toward a more mature state, potentially reducing their ability to survive and remain effective.

The UCLA team investigated whether p53 could help address these problems. Often called the “guardian of the genome,” p53 normally helps prevent damaged cells from developing into cancer. Researchers treated human T cells with navtemadlin, an experimental drug that increases p53 activity by blocking MDM2, a protein that normally keeps p53 under control.

The researchers then engineered the T cells to recognize a protein found on certain melanoma cells and monitored their activity for nearly seven days. Cells exposed to navtemadlin became more effective at killing melanoma cells, with the difference becoming apparent after about 40 hours and continuing throughout the experiment.

The treated cells also had greater energy reserves and were more likely to produce interferon-gamma and granzyme B, proteins involved in coordinating immune attacks and destroying cancer cells. They were also more likely to develop into central memory T cells, which can persist and multiply when they encounter their target again.

However, the effect depended on the drug’s concentration. Lower doses promoted memory T-cell characteristics without substantially reducing cell survival, while higher concentrations caused more cells to die.

Joseph Crompton, senior author of the study, said the findings provide a new connection between p53 and T-cell exhaustion and could open another avenue for improving cancer immunotherapies.

The study, published in Frontiers in Immunology, was conducted entirely in laboratory models. The researchers have not yet established whether the approach improves cancer treatment outcomes in patients. Further studies will be needed to determine whether temporarily activating p53 can safely improve engineered T-cell therapies in clinical settings.

Leave a Reply

Your email address will not be published. Required fields are marked *